We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Hutchmed (China) Limited 28 March 2024 Press Release HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or...
Hutchmed (China) Limited 22 March 2024 Press Release HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia...
Hutchmed (China) Limited 14 March 2024 Grant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan Hong Kong, Shanghai, & Florham Park, NJ: Thursday...
Hutchmed (China) Limited 05 March 2024 Vesting of awards under the Long Term Incentive Plan Hong Kong, Shanghai & Florham Park, NJ - Tuesday, March 5, 2024: HUTCHMED (China) Limited...
Hutchmed (China) Limited 28 February 2024 Press Release Publication of Form 20-F Hong Kong, Shanghai & Florham Park, NJ: Wednesday, February 28, 2024: HUTCHMED (China) Limited...
Hutchmed (China) Limited 28 February 2024 HUTCHMED Reports 2023 Full Year Results and Provides Business Updates Revenue grew 97% (102% CER) to US$838 million, with net income of US$101...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -5.5 | -2.01834862385 | 272.5 | 277 | 254.5 | 57858 | 266.57659735 | DE |
4 | 23 | 9.4262295082 | 244 | 303 | 216.5 | 80674 | 265.74598815 | DE |
12 | -8 | -2.90909090909 | 275 | 303 | 190.4 | 63348 | 241.14718214 | DE |
26 | -6 | -2.1978021978 | 273 | 338 | 190.4 | 89324 | 279.95012713 | DE |
52 | 46.5 | 21.0884353741 | 220.5 | 338 | 173.6 | 69907 | 260.4192022 | DE |
156 | -127 | -32.2335025381 | 394 | 656 | 130 | 111672 | 335.15481086 | DE |
260 | -178.00000663 | -40.0000008939 | 445.00000663 | 656 | 130 | 97893 | 355.07670722 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions